Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goyal, M.
Right arrow Articles by Singer, N. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goyal, M.
Right arrow Articles by Singer, N. G.
Related Collections
Right arrow Autoimmune diseases
Right arrow Epilepsy surgery
NEUROLOGY 2007;69:640-643
© 2007 American Academy of Neurology

Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations

M. Goyal, MD, M. L. Cohen, MD, B. A. Bangert, MD, S. Robinson, MD and N. G. Singer, MD

From the Divisions of Pediatric Neurology (M.G.), Pediatric Neurological Surgery (S.R.), and Pediatric Rheumatology (N.G.S.) and Departments of Pathology (M.L.C.) and Radiology (B.A.B.), Division of Rainbow Babies and Children's Hospital, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH.

Address correspondence and reprint requests to Dr. M. Goyal, 11100 Euclid Ave., M/S 6090, Cleveland, OH 44106-6090 Monisha.Goyal{at}uhhospitals.org

Rasmussen syndrome (RS) is a clinical diagnosis characterized by persistent focal seizures in a previously healthy child. Occasionally, the typical features of RS may be followed by another diagnosis. We discuss the course of a 12-year-old girl who presented with RS but was later diagnosed with CNS granulomatous disease and NOD2/CARD15 mutations. Her response to infliximab suggests that it should be included in immune-modulatory therapies used to treat these refractory disorders.

Disclosure: Dr. N.G. Singer has consulted for Abbott Immunology and engaged in sponsored research for Amgen. The other authors report no conflicts of interest.

Received November 17, 2006. Accepted in final form March 13, 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.